Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

109.08 +2.46 (+2.31%)
Streaming Delayed Price Updated: 11:01 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
News headline image
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
News headline image
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
News headline image
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
From BioNTech SE
Via GlobeNewswire
News headline image
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
News headline image
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
From BioNTech SE
Via GlobeNewswire
News headline image
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 10, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
News headline image
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 09, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
News headline image
BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BNTX DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
BNTX DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 08, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.